n e w s r e l e a s e Exhibit 99.2 Humana Inc. 500 West Main Street P.O. Box 1438 Louisville, KY 40202 http://www.humana.com FOR MORE INFORMATION CONTACT: Lisa Stoner Humana Investor Relations (502) 580-2652 e-mail: LStamper@humana.com Mark Taylor Humana Corporate Communications (317) 753-0345 e-mail: MTaylor108@humana.com Humana Reports Second Quarter 2025 Financial Results; Raises Full Year 2025 Adjusted EPS and Revenue Guidance LOUISVILLE, KY (July 30, 2025) – Humana Inc. (NYSE: HUM) today reported conso ...

Core Insights - Humana (HUM) is expected to report quarterly earnings of $6.32 per share, reflecting a decline of 9.2% year over year, while revenues are forecasted to reach $31.78 billion, an increase of 8.2% year over year [1] Earnings Estimates - Analysts have revised the consensus EPS estimate down by 0.1% over the past 30 days, indicating a collective reassessment of projections [1][2] Revenue Breakdown - 'Revenues- Premiums' are projected to be $30.23 billion, showing a year-over-year increase of 7.4% [4] - 'Revenues- Services' are estimated at $1.31 billion, indicating a significant year-over-year growth of 19% [4] - 'Revenues- Investment income (loss)' is expected to be $270.96 million, reflecting a decline of 9.1% from the previous year [4] - 'Revenue- Insurance' is anticipated to reach $30.71 billion, marking a 7.7% increase from the prior year [5] Membership Metrics - 'Medical Membership - Medicare stand-alone PDP' is projected to reach 2.45 million, up from 2.34 million in the same quarter last year [6] - 'Medical Membership - State-based contracts and other' is expected to be 1.62 million, compared to 1.39 million a year ago [6] - 'Medical Membership - Group Medicare Advantage' is estimated at 562.63 thousand, an increase from 544.90 thousand year-over-year [7] - 'Medical Membership - Medicare Supplement' is forecasted to reach 419.63 thousand, up from 339.20 thousand in the same quarter last year [7] - 'Medical Membership - Individual Medicare Advantage' is expected to decline to 5.18 million from 5.62 million year-over-year [8] - Total 'Medical Membership - Total Medicare' is projected at 8.19 million, down from 8.50 million a year ago [8] - 'Medical Membership - Military services' is estimated to be 4.94 million, compared to 5.96 million in the previous year [9] Stock Performance - Humana shares have decreased by 1.6% over the past month, contrasting with a 4.9% increase in the Zacks S&P 500 composite [9]

Core Insights - Humana Inc. (HUM) is expected to report second-quarter 2025 results on July 30, with earnings estimated at $6.32 per share and revenues at $31.78 billion, reflecting an 8.2% year-over-year growth in revenues despite a 9.2% decline in earnings [2][6] Financial Performance Expectations - The full-year 2025 revenue estimate for Humana is $126.1 billion, indicating a 7.6% year-over-year increase, while the EPS for the current year is projected at $16.37, showing a 1% gain year-over-year [3] - Humana has consistently beaten earnings estimates in the past four quarters, with an average surprise of 14.3% [3] Earnings Prediction Model - The company has a positive Earnings ESP of +10.51% and a Zacks Rank of 3 (Hold), suggesting a likelihood of an earnings beat this quarter [4] Revenue and Income Growth - The consensus estimate for second-quarter premiums indicates a 7.4% increase year-over-year, with total Medicare expected to grow by 3.8% [7] - Operating income from the Insurance unit is projected to grow by 21.4% compared to the previous year, contributing positively to earnings [8] Cost and Membership Challenges - The CenterWell unit is expected to see a 0.4% decline in operating income, and investment income is projected to drop nearly 9% year-over-year [9] - Total operating costs are anticipated to exceed $30 billion, increasing by more than 5%, which may negatively impact the bottom line [9] - The overall benefits expense ratio is expected to worsen to 89.47%, and insurance membership is projected to decline by 5.8% year-over-year [10] Peer Performance Comparison - Centene Corporation reported a second-quarter adjusted loss per share of 16 cents, missing estimates due to rising medical costs and declining service revenues [11] - Molina Healthcare reported adjusted EPS of $5.48, slightly missing estimates due to higher medical care costs [12] - Elevance Health reported adjusted EPS of $8.84, also missing estimates due to rising medical costs, despite some offset from increasing premiums [12]

Company Overview - Humana (HUM) is expected to report a year-over-year decline in earnings of 9.2%, with an estimated EPS of $6.32 for the quarter ended June 2025, while revenues are projected to increase by 8.2% to $31.78 billion [3][12] - The earnings report is scheduled for release on July 30, and the actual results will significantly influence the stock price depending on whether they meet or exceed expectations [2][12] Earnings Estimates and Trends - The consensus EPS estimate has been revised down by 0.14% over the last 30 days, indicating a slight reassessment by analysts [4] - Humana's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +10.51%, suggesting a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Humana exceeded the expected EPS of $9.98 by delivering $11.58, resulting in a surprise of +16.03% [13] - Over the past four quarters, Humana has consistently beaten consensus EPS estimates [14] Industry Context - UnitedHealth Group (UNH), another player in the Zacks Medical - HMOs industry, is expected to report a year-over-year EPS decline of 27.4%, with revenues projected at $111.6 billion, up 12.9% [18] - UnitedHealth's consensus EPS estimate has been revised down by 4.5% in the last 30 days, leading to a negative Earnings ESP of -13.1%, combined with a Zacks Rank of 4 (Sell), making it difficult to predict an earnings beat [19]

Core Insights - Humana Inc. is accelerating efforts to streamline prior authorization processes to enhance care request approvals and reduce administrative burdens for physicians [1][3] - The company aims to improve the healthcare system's complexity and navigation challenges as highlighted by its CEO [2] Group 1: Prior Authorization Reforms - Humana plans to reduce prior authorization requirements by approximately one-third for outpatient services by January 1, 2026 [6] - The company will eliminate authorization requirements for specific diagnostic services, including colonoscopies and certain imaging tests [6] - By 2026, Humana aims to provide decisions within one business day for at least 95% of complete electronic prior authorization requests, improving from over 85% currently [6] Group 2: Transparency and Reporting - Starting in 2026, Humana will publicly report prior authorization metrics, including approval and denial rates, as well as average decision times [3] - The company is working to expedite the implementation of new federal transparency requirements related to prior authorization [3] Group 3: Legal and Financial Implications - A recent court ruling upheld the government's decision to downgrade Humana's Medicare quality ratings, which may impact future Medicare bonus payments starting in 2026 [4] - Despite a reported decline in Humana's denial rates, the overall industry has experienced higher rejection rates [4] Group 4: Stock Performance - Humana's stock price increased by 3.18% to $230.53, although it is trading near its 52-week low of $206.87 [5]

Core Viewpoint - Humana Inc. is currently consolidating but may soon reverse and rally due to being oversold and approaching a support level, indicating bullish dynamics [1]. Group 1: Stock Dynamics - A stock typically remains within its usual trading range, and when it is pushed below this range by aggressive sellers, it is considered oversold [2]. - The concept of reversion to the mean suggests that oversold stocks often attract buyers who expect a price increase, potentially leading to a self-fulfilling prophecy [2]. Group 2: Indicators and Support Levels - The stochastic indicator is commonly used to determine if a stock is oversold, with lower red and blue lines indicating such conditions, which is currently the case for Humana [4]. - Humana is nearing a previously established support level, which could be bullish as remorseful sellers may place buy orders if the stock returns to this price [5]. - A significant number of buy orders at the support level could reinforce this support, creating a favorable environment for a price increase [6].

Core Viewpoint - The Villages Health (TVH) is undergoing a strategic restructuring, including a voluntary Chapter 11 bankruptcy filing, to enhance patient care and maintain daily operations [1][2]. Company Overview - TVH is a premier healthcare provider in North Central Florida, operating primary and specialty care centers, and serving over 55,000 patients, many of whom are Medicare beneficiaries [5][9]. Strategic Actions - TVH has entered into a "stalking horse" Asset Purchase Agreement with CenterWell Senior Primary Care, which will acquire TVH's assets, including eight primary care centers and two specialty care centers [2][3]. - The transaction is contingent upon a court order following an auction process, allowing other parties to submit offers [2]. Operational Continuity - During the sale process, TVH will continue to operate without interruption, ensuring high-quality healthcare services for patients [2][4]. - Patients are expected to retain access to their current providers post-transaction, regardless of their insurance plans [2]. Leadership Statements - TVH leadership emphasizes that the restructuring plan is in the best interest of patients and the community, aiming for a promising future under CenterWell [3][4]. - CenterWell expresses commitment to improving patient health through a personalized and integrated care approach [5]. Financial Context - TVH has been addressing issues related to Medicare billing practices, which may involve hundreds of millions of dollars in overpayments and potential penalties, independent of the transaction with CenterWell [6].

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving ...

Group 1 - The Senate's rules committee recently rejected a key provision of the "grand plan" pushed by the Trump administration, which aimed to limit states from obtaining federal funds through taxes on Medicaid service providers [1] - The proposed provision sought to freeze the long-standing tax mechanism used by 49 states to collect taxes from hospitals and clinics providing Medicaid services, with the Senate version suggesting more aggressive adjustments to significantly reduce such tax scales [1] - The ruling from the Senate rules committee represents a significant setback for the legislative process of this controversial provision, as it is rare for the Senate to overturn the committee's decisions [1] Group 2 - The policy battle has significant implications for the U.S. health insurance industry, with stocks of companies deeply involved in Medicaid programs, such as Centene and Molina Healthcare, experiencing increases following the Senate's ruling [2] - National comprehensive insurers like UnitedHealth and Humana, as well as integrated healthcare groups like CVS Health and Cigna, also saw their stock prices rise in response to the news [2]

Core Insights - The article introduces Gevork Avtandilov as a new contributing analyst for Seeking Alpha, highlighting his extensive experience in finance and investment banking [2]. Group 1: Analyst Background - Gevork Avtandilov has 13 years of experience in finance, starting his career in Italy with degrees in Economics and Management [2]. - He specializes in working with wealthy clients, family offices, and entrepreneurs, focusing on portfolio management, risk assessment, and cross-border investments [2]. - His analytical approach combines macroeconomic trends with in-depth sector research, particularly in financials, consumer staples, and infrastructure [2]. Group 2: Analytical Focus - The analyst emphasizes the importance of evaluating a company's balance sheet and the sustainability of its dividends for long-term investment strategies [2]. - The goal is to provide thoughtful breakdowns of sectors and economic developments, aiming for clarity and usefulness in investment analysis [2]. - Engaging in discussions with other investors is seen as a valuable aspect of the investment process, fostering deeper insights [2].